PANIRINOX Phase II Clinical Trial

Blood samples from patients with mCRC were obtained in the framework of the ongoing PANIRINOX phase II randomized clinical trial that compare the efficacy of FOLFIRINOX + panitumumab versus mFOLFOX6 + panitumumab in patients with mCRC selected on the basis of RAS and B-RAF status in circulating DNA (Protocol n. UC-0110/1608. EudraCT n. 2016-001490-33). All patients signed a written informed consent before inclusion. This trial involves 31 French hospitals/cancer centers and was approved by the Sud Méditerranée IV ethics committee. This cohort study was approved by Unicancer, the sponsor of the PANIRINOX study, and by the Agence Nationale de Sécurité du Médicament et des Produits de Santé and the Comités de Protection des Personnes, according to the French national regulatory requirements. Blood samples from HI were provided by the “Etablissement Français du Sang, the blood transfusion center of Montpellier, France (Agreement EFS-PM n. 21PLER2015-0013). All methods were carried out in accordance with relevant guidelines and regulations.

Free full text: Click here

Grosgeorges M., Picque Lasorsa L., Pastor B., Prévostel C., Crapez E., Sanchez C., Frayssinoux F., Jarlier M., Pezzella V., Monard L., Ychou M., Thierry A.R., Mazard T, & Blache P. (2023). A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer. Scientific Reports, 13, 2739.

Publication 2023

B dna Blood Blood transfusion Ethics committee Folfirinox Panitumumab Patients

Corresponding Organization :

Other organizations : Institut de Recherche en Cancérologie de Montpellier, UniCancer Group, Universidad Católica Cecilio Acosta

Top 5 similar protocols

Variable analysis

independent variables

FOLFIRINOX + panitumumab
MFOLFOX6 + panitumumab

dependent variables

Efficacy

control variables

RAS and B-RAF status in circulating DNA
Patients with mCRC

positive controls

Blood samples from HI (healthy individuals) provided by the Etablissement Français du Sang

negative controls

Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!